Ede G, Bernstein M, Calabrese L, Campbell I H, Laurent N, Palmer C M, Sethi S, Zupec-Kania B (2026) Front. Nutr. Volume 13 - 2026 https://doi.org/10.3389/fnut.2026.1749406
Web URL: Read this research on Frontiers
Background:
Metabolic dysfunction is emerging as an important contributor to the pathophysiology of major depressive disorder, bipolar disorder, and schizophrenia, fueling interest in ketogenic metabolic therapy (KMT) as a potentially beneficial intervention for serious mental illness. KMT has been used successfully for decades in treating epilepsy, but evidence for treating mental illness has yet to mature.
Aims:
This study aimed to produce expert-informed guidance for the implementation of KMT in adults with serious mood and psychotic disorders.
Method:
A modified Delphi methodology was used to examine the opinions of KMT-experienced mental health experts. A steering group of eight such experts convened to develop an online survey comprising 33 statements regarding 1) the definition of KMT in the context of serious mood and psychotic illness; 2) identification of eligible candidates; 3) monitoring and measurement standards; and 4) best practices in employing KMT. This survey was distributed to clinician peers to examine opinions. The threshold for consensus agreement was set a priori at 75%.
Result:
Consensus was reached for all 33 statements (100%); therefore, the steering group approved the complete series of recommendations.
Conclusions:
This consensus provides expert-informed guidance to support the use of KMT in adults with major depressive disorder, bipolar disorder, and schizophrenia.